Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.

Kazumasa AkagiHirokazu Taniguchi Minoru FukudaTakuya YamazakiSawana OnoHiromi TomonoTakayuki SuyamaMidori ShimadaHiroshi GyotokuShinnosuke TakemotoHiroyuki YamaguchiYosuke DotsuHiroaki SenjuHiroshi SodaTakashi MizowakiYoshio MonzenTakaya IkedaSeiji NagashimaYutaro TasakiDaisuke NakamuraKazutoshi KomiyaKatsumi NakatomiEisuke SasakiKoichi HirakawaHiroshi Mukae

Published in: Thoracic cancer (2022)

is expected to be tolerated and acceptable. Here, we aim to determine whether treatment with AP and concurrent AHTRT would be an optimal choice with manageable toxicities for LD-SCLC.

Keyphrases

small cell lung cancer
locally advanced
randomized controlled trial
early stage
spinal cord
transcription factor
rectal cancer
radiation induced
combination therapy
replacement therapy
smoking cessation